- Home
- OBIO vs UIS Comparison
OBIO vs UIS Comparison
Compare OBIO & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- UIS
- Stock Information
- Founded
- OBIO 2017
- UIS 1942
- Country
- OBIO United States
- UIS United States
- Employees
- OBIO N/A
- UIS N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- UIS EDP Services
- Sector
- OBIO Health Care
- UIS Technology
- Exchange
- OBIO Nasdaq
- UIS Nasdaq
- Market Cap
- OBIO 147.8M
- UIS 271.5M
- IPO Year
- OBIO N/A
- UIS N/A
- Fundamental
- Price
- OBIO $2.46
- UIS $3.98
- Analyst Decision
- OBIO Strong Buy
- UIS Strong Buy
- Analyst Count
- OBIO 4
- UIS 3
- Target Price
- OBIO $14.00
- UIS $7.17
- AVG Volume (30 Days)
- OBIO 247.4K
- UIS 662.5K
- Earning Date
- OBIO 11-11-2025
- UIS 10-28-2025
- Dividend Yield
- OBIO N/A
- UIS N/A
- EPS Growth
- OBIO N/A
- UIS N/A
- EPS
- OBIO N/A
- UIS N/A
- Revenue
- OBIO $2,944,000.00
- UIS $1,957,800,000.00
- Revenue This Year
- OBIO $29.26
- UIS N/A
- Revenue Next Year
- OBIO $10.65
- UIS $3.79
- P/E Ratio
- OBIO N/A
- UIS N/A
- Revenue Growth
- OBIO 41.61
- UIS N/A
- 52 Week Low
- OBIO $2.37
- UIS $3.56
- 52 Week High
- OBIO $6.50
- UIS $8.93
- Technical
- Relative Strength Index (RSI)
- OBIO 38.14
- UIS 50.43
- Support Level
- OBIO $2.57
- UIS $3.94
- Resistance Level
- OBIO $2.68
- UIS $4.13
- Average True Range (ATR)
- OBIO 0.13
- UIS 0.16
- MACD
- OBIO -0.02
- UIS 0.02
- Stochastic Oscillator
- OBIO 2.04
- UIS 55.81
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About UIS Unisys Corporation New
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.